Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration

This study has been terminated.
(Low recruitment rate)
Sponsor:
Collaborator:
Stanford University
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01642862
First received: July 10, 2012
Last updated: December 20, 2013
Last verified: December 2013
  Purpose

The inter- and intra-variability in the pharmacokinetic parameters of different formulations and doses of simvastatin in healthy subjects and in subjects with celiac disease in remission will be evaluated. Additionally, baseline values of pharmacokinetic parameters of simvastatin for both study groups will be determined.


Condition Intervention Phase
Celiac Disease
Drug: Simvastatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Phase I, Randomized, Open Label, Mono-centered, Prospective Study to Evaluate the Pharmacokinetics of Different Formulations and Doses of Simvastatin in Healthy Subjects and in Subjects With Celiac Disease in Remission

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Peak plasma concentration (Cmax) of simvastatin [ Time Frame: 0, 15, 30, 60, 90, 120, 180 minutes post-dose ] [ Designated as safety issue: No ]
    Determination of time-dependent concentrations of simvastatin in collected serum of each subject following oral administration of two different formulations and two different doses of simvastatin


Enrollment: 12
Study Start Date: July 2012
Estimated Study Completion Date: February 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Liquid formulation of Simvastatin Drug: Simvastatin
Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Active Comparator: Tablet formulation of Simvastatin Drug: Simvastatin
Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • If the subject is female, she is eligible to enter and participate in this study if she is physiologically incapable of becoming pregnant or has a negative urine pregnancy test at screening and at baseline visit
  • Negative Serology for Hepatitis B/C, HIV
  • Non-OATP1B1*5 carriers
  • Negative Serology for anti-transglutaminase IgA antibody, and normal levels of total IgA
  • For subjects with celiac disease, also

    • Diagnosis of celiac disease confirmed by medical history, histological evaluation of small intestinal mucosa on small bowel biopsy, and abnormal anti-transglutaminase antibody titers
    • Followed a gluten-free diet for at least one year, as verified by normal anti-transglutaminase antibody levels, Marsh 0-1 score on a follow-up biopsy within the past 12 months, and absence of any clinical signs or symptoms of celiac disease observed at diagnosis

Exclusion criteria:

  • Current smoker or quit smoking less than 2 years ago
  • Female breastfeeding or disagrees to use an effective mechanical contraceptive method (e.g. diaphragm or nonhormonal intrauterine device in combination with preservative)
  • Presence of any known on-going disease which is judged to be relevant according to the investigator, besides celiac disease for the cohort of celiac patients in remission
  • State after operations of the stomach or bowel (exception: appendectomy)
  • Participation in any other clinical trial with investigational or approved drugs within the last month before the study
  • Regular alcohol consumption of more than 25 g / day
  • Use of any prescription or non-prescription drugs (including herbal supplements) must be discontinued 30 days prior to study (exceptions: paracetamol and NSAIDs, not taken longer than 2 days in a row and not taken within the last 3 days before the study)
  • Consumption of grapefruit, star fruit, grapefruit juice, or star fruit juice must be discontinued 7 days prior to the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01642862

Locations
Switzerland
University Hospital Zurich, University Hospital Zurich, Gastroenterology and Hepatology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Stanford University
Investigators
Principal Investigator: Gerhard Rogler, Prof MD PhD University Hospital Zurich, Gastroenterology and Hepatology
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01642862     History of Changes
Other Study ID Numbers: CYPCEL-1103
Study First Received: July 10, 2012
Last Updated: December 20, 2013
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Celiac Disease
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Malabsorption Syndromes
Metabolic Diseases
Simvastatin
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014